Spots Global Cancer Trial Database for ovarian endometrioid tumor

Every month we try and update this database with for ovarian endometrioid tumor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	NCT02446600	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Clear C... Ovarian Endomet... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Prima...	Biospecimen Col... Carboplatin Cediranib Malea... Computed Tomogr... Echocardiograph... Gemcitabine Gemcitabine Hyd... Laboratory Biom... Magnetic Resona... Multigated Acqu... Olaparib Paclitaxel Pegylated Lipos... Pharmacological... Quality-of-Life...	18 Years -	National Cancer Institute (NCI)
Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	NCT02627443	Metastatic Fall... Metastatic Ovar... Metastatic Prim... Ovarian Endomet... Ovarian High Gr... Platinum-Sensit... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar...	Berzosertib Carboplatin Gemcitabine Hyd... Laboratory Biom... Pharmacological...	18 Years -	National Cancer Institute (NCI)
Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer	NCT02520115	Adnexal Mass Borderline Ovar... Ovarian Clear C... Ovarian Endomet... Ovarian Neoplas... Ovarian Serous ... Recurrent Ovari...	Dexamethasone Laboratory Biom... Valproic Acid	18 Years -	Barbara Ann Karmanos Cancer Institute
Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	NCT02627443	Metastatic Fall... Metastatic Ovar... Metastatic Prim... Ovarian Endomet... Ovarian High Gr... Platinum-Sensit... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar...	Berzosertib Carboplatin Gemcitabine Hyd... Laboratory Biom... Pharmacological...	18 Years -	National Cancer Institute (NCI)
A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer	NCT05226507	Advanced Solid ... Ovarian Cancer Ovarian Clear C... Ovarian Clear C... Ovarian Clear C... Ovarian Endomet... Ovarian Endomet... ARID1A Gene Mut...	NXP800	18 Years -	Nuvectis Pharma, Inc.
Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer	NCT04510584	Ovarian Endomet... Fallopian Tube ... Primary Periton... TP53 Mutation	Atezolizumab Bevacizumab	18 Years -	University Health Network, Toronto

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: